Eupraxia Pharmaceuticals (EPRX) Non-Current Assets (2022 - 2026)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Non-Current Assets of $3.2 million for Q1 2026, up 415.07% year-over-year from $626767.0 in Q1 2025, and up 207.03% quarter-over-quarter from $1.1 million in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Non-Current Assets (2022 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Non-Current Assets for 5 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 415.07% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $6.0 million (up 191.38% YoY), while the FY2025 annual figure was $1.1 million, up 107.93% from the prior year.
- Non-Current Assets rose to $3.2 million in Q1 2026 per EPRX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.2 million in Q1 2026 and bottomed at $420425.0 in Q1 2024.
- Historically, Non-Current Assets has averaged $860854.7 across 5 years, with a median of $533242.0 in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Assets retreated 13.14% — and 2026, when it surged 415.07%.
- Eupraxia Pharmaceuticals' Non-Current Assets stood at $533242.0 in 2022, then declined by 13.14% to $463151.0 in 2023, then advanced by 9.18% to $505677.0 in 2024, then jumped by 107.93% to $1.1 million in 2025, then surged by 207.03% to $3.2 million in 2026.
- Business Quant data shows EPRX's Non-Current Assets at $3.2 million in Q1 2026, $1.1 million in Q4 2025, and $949192.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | 949,192.00 |
| Jun 30, 2025 | 766,167.00 |
| Mar 31, 2025 | 626,767.00 |
| Dec 31, 2024 | 505,677.00 |
| Sep 30, 2024 | 474,923.00 |
| Jun 30, 2024 | 450,128.00 |
| Mar 31, 2024 | 420,425.00 |
| Dec 31, 2023 | 463,151.00 |
| Dec 31, 2022 | 533,242.00 |